Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Oncology
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer?
There are 1 clinical trial targeting Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer?
The estimated prevalence of Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer is approximately 75.0 per 100,000 population.
Deep-dive into Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis